clinical trial · NCT07298005
Sonlicromanol in Post-COVID
Michele van Vugt·phase2·recruiting·n = 80
Post COVID ConditionSonlicromanolPlacebo
brief summary
The aim of this randomized, double-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patients with post-COVID who experience post-exertional malaise (PEM).
started
Apr 1, 2026
primary completion
Feb 1, 2027
completion
Mar 1, 2027
last updated
Apr 13, 2026
official title
SON4PEM Study: Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol